P2X3 and P2X2/3 receptor antagonists

被引：1
|
作者：
Bolcskei, Hedvig [1 ]
Farkas, Bence [1 ]
机构：
[1] Gedeon Richter Plc, 10 POB 27, H-1475 Budapest, Hungary
来源：
PHARMACEUTICAL PATENT ANALYST | 2014年 / 3卷 / 01期
关键词：
D O I：
10.4155/PPA.13.70
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This review provides a concise summary of the molecular properties of the ligand-gated P2X receptors, in particular those containing the X3 subunit, as well as an overview comprising the most important patent applications on P2X3 and P2X2/3 receptor antagonists published since 2001. This review is mainly focused on small molecules with P2X3 and/or P2X2/3 antagonist properties. The most important classes of the patented compounds and conditions frequently claimed as their therapeutic targets are also discussed. Moreover, biological activity data from the cited patents and general prediction of druglikeness of the claimed compounds are also provided.
引用
收藏
页码：53 / 64
页数：12
相关论文
共 50 条
  • [21] P2X2 and P2X3 receptor expression in the human bladder urothelium and changes in interstitial cystitis
    Tempest, H
    Dixon, AK
    Sellers, LA
    Turner, WH
    Ferguson, DR
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 459 - 459
  • [22] Mechanosensitivity of mesenteric afferents to the jejunum, in mice deficient in P2X2 and P2X3 receptor subunits
    Rong, WF
    Ma, B
    Bumstock, G
    Grundy, D
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : A128 - A128
  • [23] P2X2 but not P2X3 receptor knockout mice demonstrate increased bone mass and weight
    Orriss, IR
    Knight, GE
    Burnstock, G
    Arnett, TR
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) : 1293 - 1293
  • [24] AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist
    Gever, Joel R.
    Soto, Rothschild
    Henningsen, Robert A.
    Martin, Renee S.
    Hackos, David H.
    Panicker, Sandip
    Rubas, Werner
    Oglesby, Ian B.
    Dillon, Michael P.
    Milla, Marcos E.
    Burnstock, Geoffrey
    Ford, Anthony P. D. W.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (06) : 1387 - 1398
  • [25] Possible involvement of P2X2 and P2X3 subtypes in neuropathic pain in mice
    Ueno, S
    Moriyama, T
    Kamiya, H
    Sakurada, T
    Katsuragi, T
    [J]. DRUG DEVELOPMENT RESEARCH, 2002, 56 (04) : 577 - 577
  • [26] In vitro and in vivo characterisation of P2X3/P2X2X3 antagonists for pain
    Bahrenberg, Gregor
    Christoph, Thomas
    Schiene, Klaus
    Kless, Achim
    Illes, Peter
    [J]. PURINERGIC SIGNALLING, 2012, 8 (01) : 122 - 123
  • [27] Localization of P2X2 and P2X3 receptors in rat trigeminal ganglion neurons
    Staikopoulos, V.
    Sessle, B. J.
    Furness, J. B.
    Jennings, E. A.
    [J]. NEUROSCIENCE, 2007, 144 (01) : 208 - 216
  • [28] Impairment of the splenic immune system in P2X2/P2X3 knockout mice
    Coutinho-Silva, R
    Knight, GE
    Burnstock, G
    [J]. IMMUNOBIOLOGY, 2005, 209 (09) : 661 - 668
  • [29] P2X3 RECEPTOR ANTAGONISTS FROM SPIDER VENOM
    Vassilevski, Alexander
    [J]. TOXICON, 2020, 177 : S3 - S3
  • [30] New purine derivatives as P2X3 receptor antagonists
    Volpini, Rosaria
    Buccioni, Michela
    Dal Ben, Diego
    Lambertucci, Catia
    Marucci, Gabriella
    Sundukova, Maya
    Nistri, Andrea
    Cristalli, Gloria
    [J]. PURINERGIC SIGNALLING, 2012, 8 (01) : 145 - 146
12345